Acute streptococcal pharyngitis in pediatric medicine: Current issues in diagnosis and management

Pediatric Drugs

Volumn 5, Issue SUPPL. 1, 2003, Pages 13-23

  Shulman, Stanford T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; MACROLIDE; PENICILLIN G; PROCAINE PENICILLIN;

ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; GASTROINTESTINAL SYMPTOM; HUMAN; PHARYNGITIS; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; REVIEW; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; SYMPTOM;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; PATIENT COMPLIANCE; PHARYNGITIS; PRACTICE GUIDELINES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0041832171     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Hayes CS, Williamson Jr H. Management of Group A beta-hemolytic streptococcal pharyngitis. Am Fam Physician 2001; 63 (8): 1557-64
2. Bisno AL, Gerber MA, Gwaltney Jr JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002; 35 (2): 113-25
3. Dajani A, Taubert K, Ferrieri P, et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics 1995; 96 (4): 758-764
4. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002; 287 (23): 3096-102
5. American Academy of Pediatrics. 2000 Red Book: Report of the Committee on Infectious Diseases. In: Pickering LK, editor. 25th ed. Elk Grove Village, IL, 2000: 526-36
6. Catanzaro FJ, Stetson CA, Morris AJ. The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med 1954; 17: 749-56
7. Tanz RR, Kabat W, Kabat K, et al. U.S. Community-Based Surveillance of Macrolide Resistance of Pharyngeal Group A Streptococci. [online] Available from URL: http://www.journals.uchicago.edu/IDSA/2002Abstracts/OralPoster.pdf. [Accessed 2002 Oct 8]
8. Kaplan EL, Johnson DR, Del Rosario MC, et al. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999; 18 (12): 1069-72
9. Martin JM, Green M, Barbadora KA, et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002 Apr 18; 346 (16): 1200-6
10. Amoxil [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
11. Feder HM, Jr., Gerber MA, Randolph MF, et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103 (1): 47-51
12. Shvartzman P, Tabenkin H, Rosentzwaig A, et al. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306 (6886): 1170-2
13. Dykhuizen RS, Golder D, Reid TM, et al. Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. J Antimicrob Chemother 1996; 37 (1): 133-8
14. Esposito S, De Ritis G, D'Errico G, et al. Clinical comparison of cefaclor twice daily versus amoxicillin-clavulanate or erythromycin three times daily in the treatment of patients with streptococcal pharyngitis. Clin Ther 1998; 20 (1): 72-9
15. Zuckerman JM. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am 2000; 14 (2): 449-62
16. Bingen E, Leclercq R, Fitoussi F, et al. Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002; 46 (5): 1199-203
17. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31 (Suppl E): S89-94
18. O'Doherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1996; 15 (9): 718-24
19. Pacifico L, Scopetti F, Ranucci A, et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996; 40 (4): 1005-8
20. Schaad UB, Heynen G. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. Pediatr Infect Dis J 1996; 15 (9): 791-5
21. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993; 31 (Suppl E): S95-101
22. Ioannidis JP, Contopoulos-Ioannidis DG, Chew P, et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother 2001; 48 (5): 677-89
23. Cohen R, Reinert P, De La Rocque F, et al. Comparison of two doses of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsilopharyngitis. Pediatr Infect Dis J 2002; 21 (4): 297-303
24. Schaad UB, Kellerhals P, Altwegg M. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002; 21 (4): 304-8
25. McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17 (1): 14-26
26. Schrock CG. Clarithromycin vs penicillin in the treatment of streptococcal pharyngitis. J Fam Pract 1992; 35 (6): 622-6
27. Kaplan EL, Gooch IW, Notario GF, et al. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin Infect Dis 2001; 32 (12): 1798-802
28. Venuta A, Laudizi L, Beverelli A, et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res 1998; 26 (3): 152-8
29. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991; 10 (4): 275-81
30. Shulman ST, Gerber MA, Tanz RR, et al. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13 (1): 1-7
31. Gerber MA, Tanz RR, Kabat W, et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics 1999; 104 (4): 911-17
32. Pichichero ME. Evaluating the need, timing and best choice of antibiotic therapy for acute otitis media and tonsillopharyngitis infections in children. Pediatr Infect Dis J 2000; 19 (12 Suppl): S131-40
33. Brook I, Aronovitz GH, Pichichero ME. Open-label, parallel-group, multicenter, randomized study of cefprozil versus erythromycin in children with group A streptococcal pharyngitis/tonsillitis. Clin Ther 2001; 23 (11): 1889-900
34. Gooch 3rd WM, Swenson E, Higbee MD, et al. Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. Clin Ther 1987; 9 (6): 670-7
35. Milatovic D, Adam D, Hamilton H, et al. Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis. Antimicrob Agents Chemother 1993; 37 (8): 1620-3
36. Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr Infect Dis J 2000; 19 (12 Suppl): S141-6
37. Guttendorf RJ, Andrews JM, Wise R, et al. Penetration of cefdinir into tonsil tissue. Pharmaceutical Research 1996 September; 13 (9 Suppl): S-468
38. Nemeth MA, McCarty J, Gooch 3rd WM, et al. Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Clin Ther 1999; 21 (11): 1873-81
39. Tack KJ, Henry DC, Gooch WM, et al. Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Antimicrob Agents Chemother 1998; 42 (5): 1073-5
40. Tack KJ, Hedrick JA, Rothstein E, et al. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group. Arch Pediatr Adolesc Med 1997; 151 (1): 45-9
41. Nemeth MA, Gooch 3rd WM, Hedrick J, et al. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin Ther 1999; 21 (9): 1525-32
42. Powers JL, Gooch 3rd WM, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000; 19 (12 Suppl): S174-80
43. Pichichero ME, Gooch WM, Rodriguez W, et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148 (10): 1053-60
44. Portier H, Chavanet P, Waldner-Combernoux A, et al. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis 1994; 26 (1): 59-66
45. Steele RW, Thomas MP, Begue RE. Selection of pediatric antibiotic suspension: taste and cost factors. Infect Med 1999; 16: 197-200
46. Mehra S, van Moerkerke M, Welck J, et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J 1998; 17 (6): 452-7
47. Gooch 3rd WM, McLinn SE, Aronovitz GH, et al. Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streptococcal pharyngitis. Antimicrob Agents Chemother 1993; 37 (2): 159-63
48. Adam D, Scholz H, Helmerking M. Comparison of short-course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis. J Antimicrob Chemother 2000; 45 Suppl: S23-30
49. Aujard Y, Boucot I, Brahimi N, et al. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J 1995; 14 (4): 295-300
50. Adam D, Hostalek U, Troster K. 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Infection 1995; 23 (Suppl 2): S83-6
51. Kaplan EL, Gastanaduy AS, Huwe BB. The role of the carrier in treatment failures after antibiotic for group A streptococci in the upper respiratory tract. J Lab Clin Med 1981 Sep; 98 (3): 326-35
52. Kaplan EL. The group A streptococcal upper respiratory tract carrier state: an enigma. J Pediatr 1980 Sep; 97 (3): 337-45
53. Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr 1991; 119 (1): 123-28
54. Tanz RR, Shulman ST, Barthel MJ, et al. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr 1985; 106 (6): 876-80
55. Rosen C, Christensen P, Hovelius B, et al. Effect of pneumococcal vaccination on upper respiratory tract infections in children. Design of a follow-up study. Scand J Infect Dis 1983; 39 Suppl: S39-44
56. Christensen P, Hovelius B, Prellner K, et al. Effects of pneumococcal vaccination on tonsillo-pharyngitis and upper respiratory tract flora. Int Arch Allergy Appl Immunol 1985; 78 (2): 161-6
57. Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A strep-tococcal vaccine. Infect Immun 2002; 70: 2171-77